title: Prevention of infection in children and adolescents with primary immunodeficiency disorders.
abstract: BACKGROUND
  Primary Immunodeficiency diseases (PIDs) are a heterogenous group of inherited disorders that may involve one or multiple components of the immune system. PIDs are uncommon, chronic and severe disorders, in which patients cannot mount a sufficiently protective immune response, leading to an increased susceptibility to infections. This review addresses the current practices for the prevention of infection in children and adolescents with PIDs, particular covering immunisations and antimicrobial prophylaxis.
  
  
  RESULTS
  Over recent years, there have been major advances in molecular and cellular understanding in the field of PIDs. Many different disorders are recognised with variable spectra of infection susceptibility depending on the particular aspects of the immune response that are affected. Immunoglobulin prophylaxis is the mainstay of treatment for PIDs and provides passive protection. Prophylactic antimicrobials are efficacious in children and adolescents with predominant defects in primary T cell immunodeficiency diseases and phagocytic disorders, and also with predominant defects in antibody production. Prophylactic antibiotics are suggested for patients with antibody deficiency diseases if recurrent infections exceed three per year, if severe infections occur despite adequate immunoglobulin replacement and in hypogammaglobulinaemic patients who have bronchiectasis. Certain immunisations are effective in antibody deficiencies, T cell deficiencies, complement deficiencies and phagocytic disorders.
  
  
  CONCLUSIONS
  There are remarkably few published data relating to clinical management aimed at preventing infectious complications in children and adolescents with PIDs. The cornerstones of the prevention of infection in most PID patients are: antimicrobial prophylaxis, appropriate vaccination, immunoglobulin replacement, for the more severe cases, and regular ongoing follow-up.
authors: Fourth Department of Pediatrics Aristotle University of Thessaloniki, General Regional Hospital Papageorgiou, Ring Road 56403 Thessaloniki, Greece. efiala@otenet.gr
authors: Efimia
authors: E
authors: Papadopoulou-Alataki
authors: Amel
authors: A
authors: Hassan
authors: E Graham
authors: EG
authors: Davies
mesh_terms: D000293:Adolescent; D000890:Anti-Infective Agents / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007116:Immunization, Passive; D007136:Immunoglobulins / Q000627:therapeutic use*; D007153:Immunologic Deficiency Syndromes / Q000150:complications / Q000276:immunology; D007223:Infant; D017053:Infection Control / Q000379:methods*; D007239:Infections / Q000209:etiology / Q000276:immunology; D008297:Male; D014611:Vaccination
chemical_list: D000890:Anti-Infective Agents; D007136:Immunoglobulins